找回密码
 立即注册
首页 Daily China 查看内容
  • QQ空间

[突破]China develops convalescent plasma therapy for COVID-19 patients

2020-2-14 16:18

 

According to clinical results, 12 to 24 hours after the patients received the treatment, they have shown improved clinical symptoms.

 

BEIJING, Feb. 14 (Xinhua) -- China has developed convalescent plasma to treat patients who are infected with the novel coronavirus (COVID-19), according to the China National Biotec Group.

 

The company said they have collected plasma from some recovered patients to prepare therapeutic products including convalescent plasma and immune globulin.

 

After strict blood biosafety tests, virus inactivation and antiviral activity tests, they have successfully developed convalescent plasma for clinical treatment and have used it to treat critically ill patients.

 

The company has set up a team to use special equipment to collect plasma from recovered patients in Wuhan since Jan. 20.

 

Three critically ill patients in a hospital in the Jiangxia District of Wuhan received convalescent plasma treatment on Feb. 8. Currently, more than 10 critically ill patients have received the treatment, according to the company.

 

According to clinical results, 12 to 24 hours after the patients received the treatment, they have shown improved clinical symptoms, with main inflammatory indexes decreased significantly and some key indexes such as blood oxygen saturation improving comprehensively.

 

根据临床结果,患者在接受治疗12 ~ 24小时后,临床症状有所改善。


北京,2月14日(新华)——据中国生物科技集团公司称,中国已经开发出治疗新型冠状病毒(covid19)感染者的恢复期血浆。


该公司表示,他们已经收集了一些康复病人的血浆,准备治疗产品,包括恢复期血浆和免疫球蛋白。


经过严格的血液生物安全测试、病毒灭活和抗病毒活性测试,他们成功地开发了用于临床治疗的恢复期血浆,并将其用于治疗危重病人。


自1月20日起,该公司已经在武汉成立了一个团队,使用专门的设备来收集康复病人的血浆。


2月8日,武汉江夏地区一家医院的3名危重病人接受了恢复期血浆治疗。据该公司称,目前已有10多名危重病人接受了这种治疗。


临床结果显示,患者接受治疗后12 ~ 24小时临床症状改善,主要炎症指标明显下降,血氧饱和度等关键指标全面改善。

 

来自: xinhua